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We  recently  discussed  the  role  of  implantable  cardioverter
deﬁbrillators  (ICDs)  as  a  complement  to  optimal  medical
management  in  patients  with  life-threatening  ventricular
arrhythmias  (VAs)  due  to  coronary  artery  spasm,  in  light  of
three  cases  managed  in  our  department  [1]. As  we  stated,  an
ICD  is  not  indicated  in  primary  prevention  in  patients  with-
out  a  spasm-related  life-threatening  VA.  However,  the  role
of  an  ICD  in  secondary  prevention  after  resuscitated  sudden
cardiac  death  due  to  vasospastic  angina  is  unknown.  Indeed,
several  cases  reports  [2,3]  have  highlighted  the  risk  of
recurrent  life-threatening  VAs  in  such  patients,  despite  opti-
mal  management  (smoking  cessation,  non-dihydropyridine
calcium  channel  blockers  and/or  nitrate  derivatives  [4]).
Unfortunately,  no  clinical  trial  has  been  performed  to
provide  deﬁnitive  conclusions.  We  have  proposed  a  cascade
management  strategy  based  on  the  results  of  an  ergonovine
test  after  the  introduction  of  optimal  medical  treatment  in
such  patients,  to  consider  the  implantation  of  an  ICD  [1].
However,  this  proposition  was  based  on  clinical  experience
not  on  evidence-based  medicine,  which  is  currently  the  gold
standard  in  modern  cardiology.
In  our  previous  review  [1],  we  discussed  the  case  of
a  52-year-old  woman  who  was  initially  managed  for  a
Abbreviations: ICD, implantable cardioverter deﬁbrillator; VA,
ventricular arrhythmia.
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1875-2136/© 2014 Published by Elsevier Masson SAS.rst  non-ST-segment  elevation  myocardial  infarction  with
ngiographically  healthy  coronaries  and  who  presented  6
onths  later  with  a  cardiac  arrest  treated  by  two  shocks
elivered  by  a semi-automatic  deﬁbrillator  for  ventricular
brillation  due  to  a  recurrent  coronary  spasm,  despite  smok-
ng  cessation  and  optimal  medical  treatment  (isosorbide
ononitrate,  calcium  channel  blockers,  statin  and  aspirin).
e  decided  to  optimize  her  medical  treatment  (amlodipine,
icorandil,  nifedipine,  statin  and  dual  antiplatelet  therapy)
nd  to  implant  an  ICD.  During  the  initial  follow-up,  the  ICD
nterrogation  showed  several  episodes  of  non-sustained  ven-
ricular  tachycardia  (maximum  duration,  14  seconds).
During  a recent  face-to-face  consultation,  36  months
fter  ICD  implantation,  the  patient  described  two  episodes
f  dizziness  without  any  context  of  stress  or  risk  factors  for
oronary  spasm  (no  cold  environment,  smoky  atmosphere,
tc.).  Her  medical  treatment  was  unchanged,  with  perfect
bservance.  The  ICD  interrogation  showed  two  episodes  of
apid  ventricular  tachycardia  and  ventricular  ﬁbrillation,
ell  detected  and  successfully  treated  by  antitachycardia
acing  and  one  intracardiac  shock  (39.2  J)  (Fig.  1).  This
bservation  conﬁrmed  that  the  role  of  an  ICD  after  life-
hreatening  VA  is  important  to  deﬁne.
It  appears  crucial  to  create  a  national  registry  of  patients
ith  an  ICD  implanted  after  a  resuscitated  sudden  cardiac
eath  due  to  life-threatening  VAs  during  a  coronary  artery
pasm.  This  registry  may  be  helpful  in  evaluating  the  preva-
ence  and  incidence  of  such  patients,  but  also  to  evaluate
he  recurrence  of  life-threatening  VAs,  despite  the  intro-
uction  of  optimal  medical  management  and  the  removal  of
isk  factors.  Indeed,  the  key  point  is  to  evaluate  whether
he  risk  of  sudden  cardiac  death  is  completely  removed  by
ptimal  management  or  whether  such  patients  display  a  spe-y  optimal  medical  treatment,  leading  to  ICD  implantation.
ccording  to  these  results,  a  multicentre  randomized  clini-
al  trial  should  be  performed.
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[igure 1. Ventricular ﬁbrillation detected by an implantable card
y an intracardiac shock (39.2 J).
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